Cargando…
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
INTRODUCTION: Treatment of severe rheumatoid arthritis (RA) is currently based either on biological agents or Janus kinase/signal transducer and activator of transcription inhibitors, most often in combination with methotrexate (MTX). AIM OF THE STUDY: The aim of the study was to compare the effecti...
Autor principal: | Wisłowska, Małgorzata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238315/ https://www.ncbi.nlm.nih.gov/pubmed/35782030 http://dx.doi.org/10.5114/reum.2022.115987 |
Ejemplares similares
-
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015) -
JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020) -
Lysozyme and its biological value in rheumatoid arthritis (RA)
por: Smirnow, J, et al.
Publicado: (2001) -
Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021) -
Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
por: Malemud, Charles J.
Publicado: (2017)